A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis

NCT07330934 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

403

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Dupilumab
DRUG: Placebo
DRUG: IBI356

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.